Table 4. Cost, effectiveness and incremental cost-effectiveness ratio of different diffusion levels of PCV–13 (vs. current PPSV–23 strategy).
| Diffusion level of PCV13 vs. PPSV–23 | Vaccine cost per person | Treatment cost per person | Total cost per person | Effectiveness per person | Incremental cost | Incremental effectiveness | ICER* = (5)/(6) |
|---|---|---|---|---|---|---|---|
| ¥ | ¥ | ¥ | QALY | ¥ | QALY | ||
| (1) | (2) | (3) = (1)+(2) | (4) | (5) | (6) | ||
| 0% vs. 100% (Current strategy) | 3,860 | 20,456 | 24,316 | 14.31480 | - | - | - |
| 10% vs. 90% | 3,987 | 20,350 | 24,337 | 14.31486 | 21 | 0.00006 | 378,000 |
| 20% vs. 80% | 4,113 | 20,245 | 24,358 | 14.31491 | 42 | 0.00011 | 378,000 |
| 30% vs. 70% | 4,240 | 20,140 | 24,380 | 14.31497 | 64 | 0.00017 | 378,000 |
| 40% vs. 60% | 4,366 | 20,035 | 24,401 | 14.31503 | 85 | 0.00022 | 378,000 |
| 50% vs. 50% | 4,493 | 19,929 | 24,422 | 14.31508 | 106 | 0.00028 | 378,000 |
| 60% vs. 40% | 4,619 | 19,824 | 24,443 | 14.31514 | 127 | 0.00034 | 378,000 |
| 70% vs. 30% | 4,746 | 19,719 | 24,464 | 14.31520 | 149 | 0.00039 | 378,000 |
| 80% vs. 20% | 4,872 | 19,613 | 24,486 | 14.31525 | 170 | 0.00045 | 378,000 |
| 90% vs. 10% | 4,999 | 19,508 | 24,507 | 14.31531 | 191 | 0.00051 | 378,000 |
*ICER: incremental cost-effectiveness ratio (¥/QALY gained). All ICERs were rounded to the nearest thousand.